Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Co-administration vs staggered administration of PCV13 and acellular DTP in 3‑month-old infants
ChiCTR2200058230Phase 4Not yet recruiting
- Sponsor
- Shanxi Center for Disease Control and Prevention
- Start
- Apr 2022
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Prevnar 13 and diphtheria, tetanus, and acellular pertussis vaccine in pneumococcal disease, diphtheria, Tetanus and 1 more (2 arms), sponsored by Shanxi Center for Disease Control and Prevention. Primary endpoints: Serum IgG antibody concentration for 13 pneumococcal serotypes, Anti-diphtheria toxoid (DT) antibodies and 3 more. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
Prevnar 13diphtheria, tetanus, and acellular pertussis vaccine
03
Conditions
pneumococcal diseasediphtheriaTetanuspertussis
Beyond the preview
Go deeper on ChiCTR2200058230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058230.